BiotechTube

Humatrope

ApprovedCompleted
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Turner Syndrome

Conditions

Turner Syndrome

Trial Timeline

Dec 1, 2005 → Sep 1, 2015

NCT ID
NCT00266656

About Humatrope

Humatrope is a approved stage product being developed by Eli Lilly for Turner Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT00266656. Target conditions include Turner Syndrome.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT00266656ApprovedCompleted

Competing Products

10 competing products in Turner Syndrome

See all competitors
ProductCompanyStageHype Score
SomatropinEli LillyPhase 3
77
17 beta estradiolEli LillyPhase 3
77
Somatropin + Ethinyl estradiol + Medroxyprogesterone acetateEli LillyPhase 3
77
r-hGHMerckApproved
85
Somapacitan + Norditropin®Novo NordiskPhase 3
76
estradiolNovo NordiskApproved
84
Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patchNovo NordiskPhase 1
32
somatotropinPfizerPre-clinical
22
Lonapegsomatropin + SomatropinAscendis PharmaPhase 2
49
Somatropin (rDNA origin)IpsenPhase 3
74

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved
85
Olanzapine + PlaceboApproved
85
exenatide and sitagliptin + exenatide and placeboApproved
85
Tirzepatide + PlaceboApproved
85
tadalafilApproved
85